reduce severity and frequency of seizures
In a clinical trial of 138 people with LGS (ages 4-30) where BANZEL was added to their current therapy,2 BANZEL:
Reduced the severity
of seizures by
Reduced frequency of
tonic-atonic seizures by
of total seizures by
BANZEL for adults with LGS
The full clinical trial results were based on all of the people in the trial (including both children and adults). The clinical trial was not specifically designed to study efficacy in adults only. Actual results may vary.
The following results were based only on the adults in the trial. In the clinical trial with 138 patients, 21 adults (18 years and older) received BANZEL and 10 received placebo. These adults saw the following results3:
What to remember about treatment with BANZEL
Understand possible side effects
BANZEL is an add-on medication that can cause side effects and affect how other seizure medications work. Other medicines should not be started or stopped without talking to your doctor. Be sure to talk with your doctor for more information about the risks associated with BANZEL
- Eisai Data on File. Study No. CRUF331 0022. Release date January 26, 2005.
- BANZEL Prescribing Information.
- McMurray M. Treatment of adults with Lennox–Gastaut syndrome: further analysis of efficacy and safety/tolerability of rufinamide. Neurol Ther. 2016;5:35–43.